What I have: a GLP-1 receptor agonist · 1 mg/mL.
I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.
Assume no laboratory access beyond what I can pay a third party for.
Concretely, what should I do, and how would I know afterwards whether I did it right?
Nobody has published a cycle count, and at 1 mg/mL the concentration tells you what a wrong guess costs: a 0.1 mL aliquot holds 0.1 mg and every microlitre is 1 µg. Damage from freezing is not gradual attrition — it is concentrated at the phase transitions, where ice excludes solute and the unfrozen fraction climbs well above 1 mg/mL for as long as the transition lasts. Two slow cycles can therefore do more than four fast ones, which is why a cycle count is the wrong unit in the first place. The way to make the number one is to make it one: split at reconstitution into single-draw aliquots, label each with 1 mg/mL and the date, and never thaw a container you will refreeze.
The honest answer is that people worry about the freezer temperature and should worry about the number of cycles.
During freezing, solutes are excluded from the ice lattice and concentrate into the residual liquid. Local concentrations can rise many-fold, which promotes aggregation independently of temperature.
Never refreeze a thawed aliquot. The whole point of aliquoting is that the aliquot is single-use, and refreezing it discards the benefit.
Cryoconcentration of solutes at the ice front is a well-documented mechanism in freeze-thaw damage to proteins and peptides.
The caveat is that aggregation is invisible in a clear solution below the threshold where it becomes visible.
Dry powder tolerates cycles far better than solution does.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemOn the detail: this is one of the few handling questions with a genuinely quantitative literature behind it.
The mitigation is aliquoting. Divide the reconstituted solution into single-use volumes before the first freeze, and each aliquot then experiences exactly one cycle.
Mechanically, buffer salts crystallise at different points during freezing. Sodium phosphate is the classic example: the dibasic form crystallises first and the pH of the residual liquid falls by several units. That pH excursion is the real damage in many cases.
Aliquoting to eliminate repeated cycles is standard laboratory practice for exactly this reason.
The number of tolerable cycles is sequence- and formulation-dependent and no general number is honest.
Thaw slowly and never refreeze an aliquot.
The relevant physics is ice-front concentration: as water crystallises, everything dissolved is concentrated into the shrinking liquid phase, including buffer salts.
Thaw slowly at room temperature or in the refrigerator rather than in warm water. Rapid warming creates local thermal and concentration gradients that promote aggregation.
Count cycles rather than worrying about degrees. Minus twenty and minus eighty differ far less than one cycle and five do.
Selective crystallisation of sodium phosphate buffer components producing large pH shifts on freezing is a classical result in the lyophilisation literature.
Count cycles, not degrees. The cycle is the damaging event.
Buffer components crystallise at different rates during freezing, which shifts pH locally by a surprising amount.
Let a frozen vial reach room temperature before opening it. Opening a cold vial in humid air condenses water into the cake, which raises residual moisture and undoes what lyophilisation achieved.
Condensation onto cold lyophilised material on opening is a recognised handling error and is the basis for the equilibrate-before-opening rule.
Aliquoting itself is a handling step and introduces its own contamination opportunity.
Let a frozen vial reach room temperature before opening, or you condense water into it.
Answer first: each freeze-thaw cycle costs something through aggregation and pH shift, so the mitigation is aliquoting rather than choosing a better freezer.
A dry lyophilised powder is much less affected by a temperature cycle because there is no liquid phase for anything to concentrate into. Condensation on a cold vial opened warm is the real risk there.
Deamidation kinetics for asparagine in peptides are well characterised and strongly sequence-dependent: the residue following the asparagine dominates the rate, with glycine and serine at the n+1 position accelerating it by an order of magnitude relative to bulkier residues. That is why two peptides in the same buffer at the same temperature can have quite different shelf lives.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Aliquot before the first freeze. That is the whole answer.
edited 2 Nov 2024 by coldpack_88 — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.